Home final
Accelerating reimbursement for
Pharma & MedTech
Expert-led strategy from evidence generation through to PBS, MBS and Prescribed List acceptance.
Complex pathways.
High stakes. No room
for error.
Australian market access is among the most rigorous in the world. PBAC, MSAC and MDHTAC scrutiny is increasing — and the cost of avoidable rework cycles is significant.
- Complex reimbursement pathways across PBS, MBS and Prescribed List
- Uncertainty around clinical, economic and value evidence requirements
- Evolving PBAC, MSAC and MDHTAC expectations and increasing scrutiny
- Navigating market access for AI and digital health innovations
Faster. Stronger.
More certain.
- 01Faster progression to funding with fewer avoidable rework cycles
- 02Clinical, economic and pricing evidence built to withstand HTA and payer scrutiny
- 03Decision-ready market access strategies aligned to PBAC, MSAC and MDHTAC
- 04End-to-end submission support from strategy through to acceptance
We built Pulse Economics to bring genuine expertise — not just process — to every reimbursement challenge our clients face.
With deep expertise across PBS, MBS and Prescribed List submissions, Olivia founded Pulse Economics to deliver the calibre of strategic and analytical rigour that gives clients a genuine advantage at the committee table.
Meet Our Full Team →consulting experience
MBS & Prescribed List
biotech clients served
in our active portfolio
End-to-end market
access expertise
Evidence Strategy & Generation
Design and support clinical and real-world evidence strategies that directly address HTA, payer and policy requirements.
→ 02Market Access & Reimbursement
Guide clients through PBS, MBS and Prescribed List pathways from evidence generation to reimbursement.
→ 03Commercialisation & Growth Strategy
Commercial strategies for startups and enterprises supporting growth and lifecycle management.
→ 04Modelling & Data Analytics
Statistical, financial and economic modelling aligned with regulatory and payer expectations.
→ 05Health Policy
Supporting organisations in shaping health policy and improving outcomes at scale.
→
From strategy
to acceptance.
We begin with a thorough review of your product, clinical evidence and regulatory history to define the optimal market access pathway.
Designing clinical and economic evidence aligned with payer expectations.
We manage submissions and stakeholder engagement to accelerate approvals.
Post-approval strategy, pricing, and lifecycle optimisation support.
Organisations we've worked with
News & Insights
5 Common Mistakes in MSAC Submissions
Avoiding these errors can significantly improve your submission's success.
Pulse Economics joins national advisory group
A milestone in shaping the future of advanced therapy access.
Top 8 things device companies must know
Recent reforms have changed the reimbursement landscape.
Ready to accelerate your
market access journey?
Every successful reimbursement starts with the right strategy. Let's build yours.